Company news

NRX Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

May 28, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

May 27, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

May 21, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

May 20, 2025

IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

May 20, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

May 16, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement

May 15, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 14, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

May 13, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ: NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 11, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation

May 6, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

May 4, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

April 29, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

April 20, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

April 2, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

March 30, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

March 23, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 16, 2025

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

March 11, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

February 5, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Engage BTIG as Financial Advisor

February 2, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

January 27, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

January 27, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement

January 20, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

January 14, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

January 13, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market

January 12, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Conduct Investor Workshop at the Mar-A-Lago Club

January 9, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8...

January 6, 2025

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

January 5, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics

January 5, 2025

HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025

January 2, 2025

Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics

January 1, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

December 29, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

November 25, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

November 24, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Michael Abrams as Chief Financial Officer

November 17, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

November 13, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

November 12, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

November 6, 2024

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

October 30, 2024

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

October 29, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

October 22, 2024

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic

October 2, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)

September 29, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update

August 13, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds

August 12, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.